Neurocrine Biosciences and Takeda Pharmaceutical Co. entered a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Neurocrine was granted an exclusive license to seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia. Neurocrine will be responsible for developing and commercializing all pipeline compounds included in the collaboration. Takeda will receive a t...